F. Ivy Carroll

F. Ivy Carroll

Distinguished Fellow, Medicinal Chemistry

F. Ivy Carroll, PhD, Distinguished Fellow in medicinal chemistry, appointed August 2002, joined RTI in 1960. He served as director of the Center for Organic and Medicinal Chemistry (1975-2007) and research vice president of the Chemistry and Life Sciences Group (1996-2001). Dr. Carroll has made major scientific contributions in drug discovery and development and other research areas. Among his most recognized scientific contributions is the development of a diagnostic agent for Parkinson's disease and compounds as potential treatments for cocaine and nicotine addictions and other central nervous system disorders.

He has published more than 481 peer-reviewed publications, 34 book chapters, 43 patents, and more than 20 current patent applications. Dr. Carroll has received numerous awards for his research accomplishments, such as the 1993 Pacesetter Award, National Institute on Drug Abuse; the 1993 Distinguished Speaker Award, North Carolina Section of American Chemical Society; the 2000 Southern Chemist Award, Memphis Section of American Chemical Society; the 2001 Charles H. Herty Medal, Georgia Section of American Chemical Society; the 2001 Margaret E. Knox Excellence Award, Research Triangle Institute; the 2002 Division of Medicinal Chemistry Award, American Chemical Society; the 2006 Nathan B. Eddy Award from the College on Problems of Drug Dependence; the 2006 Research Achievement Award in Drug Design and Discovery from the American Association of Pharmaceutical Scientists; the 2010 North Carolina Award for Science; and the 2010 National Institute on Drug Abuse Public Service Award for Significant Achievement.

In 2007, he was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame.


PhD, Chemistry, University of North Carolina at Chapel Hill; BS, Chemistry, Auburn University.

Latest Publications

Rodriguez, J.S., Cunningham, C.S., Moura, F.B., Ondachi, P., Carroll, F.I., & McMahon, L.R. (2014). Discriminative stimulus and hypothermic effects of some derivatives of the nAChR agonist epibatidine in mice. Psychopharmacology, 231 (23):4455-4466.
Peterson, E.C., Hambuchen, M.D., Tawney, R.L., Gunnell, M.G., Cowell, J.L., Lay, J.O., Blough, B.E., Carroll, F.I., et al. (2014). Simple radiometric method for accurately quantitating epitope densities of hapten–protein conjugates with sulfhydryl linkages. Bioconjugate Chemistry, 25 (12):2112-2115.
Kormos, C.M., Gichinga, M.G., Maitra, R., Runyon, S.P., Thomas, J.B., Brieaddy, L.E., Mascarella, S.W., Navarro, H.A., & Carroll, F.I. (2014). Design, Synthesis, and Biological Evaluation of (3R)-1,2,3,4-Tetrahydro-7-hydroxy-N-[(1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dim ethyl-1-piperidinyl]methyl]-2-methylpropyl]-3-isoquinolinecarboxamide (JDTic) Analogues: In Vitro Pharmacology and ADME Profile. Journal of Medicinal Chemistry, 57 (17):7367-7381.
Mello, N.K., Fivel, P.A., Kohut, S.J., & Carroll, F.I. (2014). Effects of Chronic Varenicline Treatment on Nicotine, Cocaine, and Concurrent Nicotine+Cocaine Self-Administration. Neuropsychopharmacology, 39 (5):1222-1231.
View all publications by F. Ivy Carroll (591)


  • Medicinal Chemistry
  • Biochemical Addiction
  • Drug Abuse Research